Preliminary study of beta-blocker therapy on modulation of interleukin-33/ST2 signaling during ventricular remodeling after acute myocardial infarction
Abstract
Background: This study aimed to evaluate the role of b-blocker therapy on modulating interleukin (IL)-33/ST2 (interleukin-1 receptor-like 1) signaling during ventricular remodeling related to heart failure (HF) after acute myocardial infarction (AMI).
Methods: Sprague-Dawley rats that survived surgery to induce AMI were randomly divided into the placebo group and the b-blocker treatment group. A sham group was used as a control. Left ventricular (LV) function variables, the myocardial infarct size, fibrosis and IL-33/ST2 protein expression was measured.
Results: Compared with the placebo group, b-blocker treatment significantly improved LV function and reduced infarct size (p < 0.05). There was higher protein expression of IL-33 (p < 0.05) and sST2 (p < 0.05), as well as higher expression of fibrosis (p < 0.05), compared to the sham group. Notably, the high expression of cardioprotective IL-33 was not affected by b-blocker treatment (p > 0.05), however, treatment with b-blocker enhanced IL-33/ST2 signaling, with lower expression of sST2 (p < 0.05) and significantly attenuated fibrosis (p < 0.05).
Conclusions: Our study suggested that b-blocker therapy might play a beneficial role in the modulation of IL-33/ST2 signaling during ventricular remodeling. These results may be helpful in identifying IL-33/ST2 systems as putative b-blocker targets at an early stage after AMI. (Cardiol J 2017; 24, 2: 188–194)
Keywords: beta-blockerIL-33/ST2ventricular remodelingacute myocardial infarction
References
- Hunt SA, Abraham WT, Chin MH, et al. American College of Cardiology Foundation, American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009; 53(15): e1–e90.
- Sharma S, Colangelo LA, Lima J, et al. Effects of Weight and Weight Change on Cardiac Remodeling Over 20 Years: The CARDIA (Coronary Artery Risk Development in Young Adults) Study. J Am Coll Cardiol. 2015; 65(22): 2463–2465.
- Cole GD, Patel SJ, Zaman N, et al. "Triple therapy" of heart failure with angiotensin-converting enzyme inhibitor, beta-blocker, and aldosterone antagonist may triple survival time: shouldn't we tell patients? JACC Heart Fail. 2014; 2(5): 545–548.
- Fukui M, Goda A, Komamura K, et al. Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure. Heart Vessels. 2016; 31(2): 173–182.
- Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015; 443: 57–70.
- Miller AM, Liew FY. The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011; 131(2): 179–186.
- Yin H, Li P, Hu F, et al. IL-33 attenuates cardiac remodeling following myocardial infarction via inhibition of the p38 MAPK and NF-κB pathways. Mol Med Rep. 2014; 9(5): 1834–1838.
- Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011; 8(1): 22.
- Bayes-Genis A, de Antonio M, Galán A, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012; 14(1): 32–38.
- Liu Mi, Wang XR, Wang C, et al. Panax quinquefolium saponin attenuates ventricular remodeling after acute myocardial infarction by inhibiting chop-mediated apoptosis. Shock. 2013; 40(4): 339–344.
- Lax A, Sanchez-Mas J, Asensio-Lopez MC, et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Fail. 2015; 3(1): 50–58.
- Sánchez-Más J, Lax A, Asensio-López MD, et al. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. Eur J Clin Invest. 2014; 44(7): 643–651.
- Litwin SE, Katz SE, Morgan JP, et al. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994; 89(1): 345–354.
- Xia Jg, Xu Ff, Qu Y, et al. Atorvastatin post-conditioning attenuates myocardial ischemia reperfusion injury via inhibiting endoplasmic reticulum stress-related apoptosis. Shock. 2014; 42(4): 365–371.
- Wolfrum S, Dendorfer A, Schutt M, et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol. 2004; 44(3): 348–355.
- Armstrong C. ACCF and AHA Release Guidelines on the Management of Heart Failure. Am Fam Physician. 2014; 90(3): 186–189.
- Mair J, Jaffe A, Apple F, et al. Cardiac biomarkers. Dis Markers. 2015; 2015: 370569.
- Daniels LB, Bayes-Genis A. Using ST2 in cardiovascular patients: a review. Future Cardiol. 2014; 10(4): 525–539.
- Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16): 1810–1852.
- Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ Heart Fail. 2013; 6(6): 1206–1213.
- Chatterjee S, Udell JA, Sardar P, et al. Comparable benefit of β-blocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials. Can J Cardiol. 2014; 30(8): 898–903.
- Wikstrand J, Wedel H, Castagno D, et al. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med. 2014; 275(2): 134–143.
- Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail. 2013; 19(12): 821–828.
- Nguyen T, Shaheed A, Venigalla S, et al. Using beta-blockers to treat heart failure. JAAPA. 2014; 27(12): 50–55.
- Prijic S, Buchhorn R. Mechanisms of Beta-Blockers Action in Patients with Heart Failure. Rev Recent Clin Trials. 2014; 9(2): 58–60.
- Bølling R, Scheller NM, Køber L, et al. Comparison of the clinical outcome of different beta-blockers in heart failure patients: a retrospective nationwide cohort study. Eur J Heart Fail. 2014; 16(6): 678–684.
